Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis

Taku Nakagawa, Sharon K. Huang, Steve R. Martinez, Andy N. Tran, David Elashoff, Xing Ye, Roderick R. Turner, Armando E. Giuliano, Dave S B Hoon

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

To determine if protein expression in primary breast cancers can predict axillary lymph node (ALN) metastasis, we assessed differences in protein expression between primary breast cancers with and without ALN metastasis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Laser capture microdissection was performed on invasive breast cancer frozen sections from 65 patients undergoing resection with sentinel lymph node (SLN) or level I and II ALN dissection. Isolated proteins from these tumors were applied to immobilized metal affinity capture (IMAC-3) ProteinChip arrays and analyzed by SELDI-TOF-MS to generate unique protein profiles. Correlations between unique protein peaks and histologically confirmed ALN status and other known clinicopathologic factors were examined using ANOVA and multivariate logistic regression. Two metal-binding polypeptides at 4,871 and 8,596 Da were identified as significant risk factors for nodal metastasis (P = 0.034 and 0.015, respectively) in a multivariate analysis. Lymphovascular invasion (LVI) was the only clinicopathologic factor predictive of ALN metastasis (P = 0.0038). In a logistic regression model combining the 4,871 and 8,596 Da peaks with LVI, the area under the receiver operating characteristic curve was 0.87. Compared with patients with negative ALN, those with ≥2 positive ALN or non-SLN metastases were significantly more likely to have an increased peak at 4,871 Da (P = 0.016 and 0.0083, respectively). ProteinChip array analysis identified differential protein peaks in primary breast cancers that predict the presence and number of ALN metastases and non-SLN status.

Original languageEnglish (US)
Pages (from-to)11825-11830
Number of pages6
JournalCancer Research
Volume66
Issue number24
DOIs
StatePublished - Dec 15 2006
Externally publishedYes

Fingerprint

Proteomics
Lymph Nodes
Breast Neoplasms
Neoplasm Metastasis
Protein Array Analysis
Proteins
Logistic Models
Mass Spectrometry
Lasers
Metals
Laser Capture Microdissection
Frozen Sections
Lymph Node Excision
ROC Curve
Analysis of Variance
Multivariate Analysis
Peptides

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nakagawa, T., Huang, S. K., Martinez, S. R., Tran, A. N., Elashoff, D., Ye, X., ... Hoon, D. S. B. (2006). Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. Cancer Research, 66(24), 11825-11830. https://doi.org/10.1158/0008-5472.CAN-06-2337

Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. / Nakagawa, Taku; Huang, Sharon K.; Martinez, Steve R.; Tran, Andy N.; Elashoff, David; Ye, Xing; Turner, Roderick R.; Giuliano, Armando E.; Hoon, Dave S B.

In: Cancer Research, Vol. 66, No. 24, 15.12.2006, p. 11825-11830.

Research output: Contribution to journalArticle

Nakagawa, T, Huang, SK, Martinez, SR, Tran, AN, Elashoff, D, Ye, X, Turner, RR, Giuliano, AE & Hoon, DSB 2006, 'Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis', Cancer Research, vol. 66, no. 24, pp. 11825-11830. https://doi.org/10.1158/0008-5472.CAN-06-2337
Nakagawa T, Huang SK, Martinez SR, Tran AN, Elashoff D, Ye X et al. Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. Cancer Research. 2006 Dec 15;66(24):11825-11830. https://doi.org/10.1158/0008-5472.CAN-06-2337
Nakagawa, Taku ; Huang, Sharon K. ; Martinez, Steve R. ; Tran, Andy N. ; Elashoff, David ; Ye, Xing ; Turner, Roderick R. ; Giuliano, Armando E. ; Hoon, Dave S B. / Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. In: Cancer Research. 2006 ; Vol. 66, No. 24. pp. 11825-11830.
@article{25218bbb0edd45daa7ff81067a7d2782,
title = "Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis",
abstract = "To determine if protein expression in primary breast cancers can predict axillary lymph node (ALN) metastasis, we assessed differences in protein expression between primary breast cancers with and without ALN metastasis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Laser capture microdissection was performed on invasive breast cancer frozen sections from 65 patients undergoing resection with sentinel lymph node (SLN) or level I and II ALN dissection. Isolated proteins from these tumors were applied to immobilized metal affinity capture (IMAC-3) ProteinChip arrays and analyzed by SELDI-TOF-MS to generate unique protein profiles. Correlations between unique protein peaks and histologically confirmed ALN status and other known clinicopathologic factors were examined using ANOVA and multivariate logistic regression. Two metal-binding polypeptides at 4,871 and 8,596 Da were identified as significant risk factors for nodal metastasis (P = 0.034 and 0.015, respectively) in a multivariate analysis. Lymphovascular invasion (LVI) was the only clinicopathologic factor predictive of ALN metastasis (P = 0.0038). In a logistic regression model combining the 4,871 and 8,596 Da peaks with LVI, the area under the receiver operating characteristic curve was 0.87. Compared with patients with negative ALN, those with ≥2 positive ALN or non-SLN metastases were significantly more likely to have an increased peak at 4,871 Da (P = 0.016 and 0.0083, respectively). ProteinChip array analysis identified differential protein peaks in primary breast cancers that predict the presence and number of ALN metastases and non-SLN status.",
author = "Taku Nakagawa and Huang, {Sharon K.} and Martinez, {Steve R.} and Tran, {Andy N.} and David Elashoff and Xing Ye and Turner, {Roderick R.} and Giuliano, {Armando E.} and Hoon, {Dave S B}",
year = "2006",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-06-2337",
language = "English (US)",
volume = "66",
pages = "11825--11830",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis

AU - Nakagawa, Taku

AU - Huang, Sharon K.

AU - Martinez, Steve R.

AU - Tran, Andy N.

AU - Elashoff, David

AU - Ye, Xing

AU - Turner, Roderick R.

AU - Giuliano, Armando E.

AU - Hoon, Dave S B

PY - 2006/12/15

Y1 - 2006/12/15

N2 - To determine if protein expression in primary breast cancers can predict axillary lymph node (ALN) metastasis, we assessed differences in protein expression between primary breast cancers with and without ALN metastasis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Laser capture microdissection was performed on invasive breast cancer frozen sections from 65 patients undergoing resection with sentinel lymph node (SLN) or level I and II ALN dissection. Isolated proteins from these tumors were applied to immobilized metal affinity capture (IMAC-3) ProteinChip arrays and analyzed by SELDI-TOF-MS to generate unique protein profiles. Correlations between unique protein peaks and histologically confirmed ALN status and other known clinicopathologic factors were examined using ANOVA and multivariate logistic regression. Two metal-binding polypeptides at 4,871 and 8,596 Da were identified as significant risk factors for nodal metastasis (P = 0.034 and 0.015, respectively) in a multivariate analysis. Lymphovascular invasion (LVI) was the only clinicopathologic factor predictive of ALN metastasis (P = 0.0038). In a logistic regression model combining the 4,871 and 8,596 Da peaks with LVI, the area under the receiver operating characteristic curve was 0.87. Compared with patients with negative ALN, those with ≥2 positive ALN or non-SLN metastases were significantly more likely to have an increased peak at 4,871 Da (P = 0.016 and 0.0083, respectively). ProteinChip array analysis identified differential protein peaks in primary breast cancers that predict the presence and number of ALN metastases and non-SLN status.

AB - To determine if protein expression in primary breast cancers can predict axillary lymph node (ALN) metastasis, we assessed differences in protein expression between primary breast cancers with and without ALN metastasis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Laser capture microdissection was performed on invasive breast cancer frozen sections from 65 patients undergoing resection with sentinel lymph node (SLN) or level I and II ALN dissection. Isolated proteins from these tumors were applied to immobilized metal affinity capture (IMAC-3) ProteinChip arrays and analyzed by SELDI-TOF-MS to generate unique protein profiles. Correlations between unique protein peaks and histologically confirmed ALN status and other known clinicopathologic factors were examined using ANOVA and multivariate logistic regression. Two metal-binding polypeptides at 4,871 and 8,596 Da were identified as significant risk factors for nodal metastasis (P = 0.034 and 0.015, respectively) in a multivariate analysis. Lymphovascular invasion (LVI) was the only clinicopathologic factor predictive of ALN metastasis (P = 0.0038). In a logistic regression model combining the 4,871 and 8,596 Da peaks with LVI, the area under the receiver operating characteristic curve was 0.87. Compared with patients with negative ALN, those with ≥2 positive ALN or non-SLN metastases were significantly more likely to have an increased peak at 4,871 Da (P = 0.016 and 0.0083, respectively). ProteinChip array analysis identified differential protein peaks in primary breast cancers that predict the presence and number of ALN metastases and non-SLN status.

UR - http://www.scopus.com/inward/record.url?scp=33846240028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846240028&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-2337

DO - 10.1158/0008-5472.CAN-06-2337

M3 - Article

C2 - 17178879

AN - SCOPUS:33846240028

VL - 66

SP - 11825

EP - 11830

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -